These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25245321)

  • 21. Bayesian road safety analysis: incorporation of past evidence and effect of hyper-prior choice.
    Miranda-Moreno LF; Heydari S; Lord D; Fu L
    J Safety Res; 2013 Sep; 46():31-40. PubMed ID: 23932683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A projection of benefits due to fecal occult blood test for colorectal cancer.
    Wu D; Erwin D; Rosner GL
    Cancer Epidemiol; 2009 Oct; 33(3-4):212-5. PubMed ID: 19733140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing the impact of trait prevalence priors in Bayesian-based genetic prediction modeling of human appearance traits.
    Katsara MA; Branicki W; Pośpiech E; Hysi P; Walsh S; Kayser M; Nothnagel M;
    Forensic Sci Int Genet; 2021 Jan; 50():102412. PubMed ID: 33260052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
    Brenner H; Tao S
    Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.
    Lucidarme O; Cadi M; Berger G; Taieb J; Poynard T; Grenier P; Beresniak A
    Eur J Radiol; 2012 Jul; 81(7):1413-9. PubMed ID: 21444171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigating different approaches to develop informative priors in hierarchical Bayesian safety performance functions.
    Yu R; Abdel-Aty M
    Accid Anal Prev; 2013 Jul; 56():51-8. PubMed ID: 23612558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of screening data: colorectal cancer.
    Gyrd-Hansen D; Søgaard J; Kronborg O
    Int J Epidemiol; 1997 Dec; 26(6):1172-81. PubMed ID: 9447396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The utility of prior information and stratification for parameter estimation with two screening tests but no gold standard.
    Gustafson P
    Stat Med; 2005 Apr; 24(8):1203-17. PubMed ID: 15558709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic test accuracy of nutritional tools used to identify undernutrition in patients with colorectal cancer: a systematic review.
    Håkonsen SJ; Pedersen PU; Bath-Hextall F; Kirkpatrick P
    JBI Database System Rev Implement Rep; 2015 May; 13(4):141-87. PubMed ID: 26447079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Faecal occult blood test and colonoscopy use in Portugal: Results from the National Health Survey 2014.
    Khan H; Shaaban N; Peleteiro B
    J Med Screen; 2020 Dec; 27(4):171-185. PubMed ID: 31865864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
    Haug U; Hundt S; Brenner H
    Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction models for clustered data with informative priors for the random effects: a simulation study.
    Ni H; Groenwold RHH; Nielen M; Klugkist I
    BMC Med Res Methodol; 2018 Aug; 18(1):83. PubMed ID: 30081875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening.
    Parra-Blanco A; Gimeno-García AZ; Quintero E; Nicolás D; Moreno SG; Jiménez A; Hernández-Guerra M; Carrillo-Palau M; Eishi Y; López-Bastida J
    J Gastroenterol; 2010 Jul; 45(7):703-12. PubMed ID: 20157748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A hierarchical Bayesian approach to adaptive vision testing: A case study with the contrast sensitivity function.
    Gu H; Kim W; Hou F; Lesmes LA; Pitt MA; Lu ZL; Myung JI
    J Vis; 2016; 16(6):15. PubMed ID: 27105061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empirical Bayes screening of many p-values with applications to microarray studies.
    Datta S; Datta S
    Bioinformatics; 2005 May; 21(9):1987-94. PubMed ID: 15691856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of fecal immunochemical tests for colorectal cancer screening.
    Daly JM; Bay CP; Levy BT
    J Prim Care Community Health; 2013 Oct; 4(4):245-50. PubMed ID: 23799674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
    Dollinger MM; Behl S; Fleig WE
    Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests.
    Meklin J; SyrjÄnen K; Eskelinen M
    Anticancer Res; 2020 Jul; 40(7):3591-3604. PubMed ID: 32620599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.